IPM Take
The argument that childhood obesity should be treated as a medical condition rather than a failure of discipline is becoming harder to resist.
GLP-1 medicines can produce clinically meaningful weight reduction in adolescents. But announcing that the drugs are “safe and effective for children” moves faster than the evidence.
The new analysis combines only nine trials, some involving fewer than 50 participants, with follow-up lasting between five and 68 weeks. Evidence below the age of 12 remains particularly limited.
The medicine may work.
The real policy test is whether health systems can offer years of specialist monitoring, nutritional support and follow-up without turning paediatric obesity care into another privilege reserved for families with the right insurance and postcode.
Executive Summary
Researchers from the University of Western Ontario reviewed nine randomised trials involving 756 participants aged between six and 18 with obesity but without diabetes. The findings were presented at the International Congress on Obesity 2026 in Mexico City. Participants had received exenatide, liraglutide or semaglutide, with an average age of approximately 14 to 15 years.
Compared with placebo or standard care, GLP-1 receptor agonists were associated with an average between-group weight difference of 5.08 kg, alongside improvements in BMI standard-deviation scores, systolic blood pressure and health-related quality of life. Semaglutide produced the largest estimated weight difference, but that figure came from a single trial rather than a direct comparison between medicines.
Nausea was approximately three times more common with GLP-1 treatment. Other adverse events, including vomiting and diarrhoea, showed numerical increases but were not statistically significant in the pooled analysis. Serious events were rare and occurred at similar rates between treatment and control groups. However, the included trials lasted between five and 68 weeks, leaving long-term safety, treatment duration and outcomes after discontinuation uncertain.
Semaglutide injections are already authorised for obesity in adolescents aged 12 and older in the United States and European Union. They are not established for routine obesity treatment below 12 years of age. Current US paediatric guidance recommends offering approved weight-management medicines to eligible adolescents aged 12 and older as an addition to intensive health-behaviour and lifestyle treatment, not as a replacement for it.
Why it matters
- Policymakers: Paediatric obesity pathways must support continuing treatment and monitoring rather than funding a prescription without the surrounding care.
- Payers: Restrictive coverage may reserve effective therapy for wealthier families while children facing the greatest cardiometabolic risk remain untreated.
- Clinicians: Treatment decisions must consider growth, nutrition, mental health, adverse effects, family circumstances and the likelihood of sustained follow-up.
- Patients and families: GLP-1 medicines are not a shortcut or punishment. They are one possible component of chronic obesity care.
- Researchers: Longer trials are needed, especially in children under 12 and across more diverse populations.
For years, families were told that childhood obesity could be solved through greater discipline.
Eat less. Move more. Reduce screen time.
When that advice failed, the child was often blamed.
The arrival of GLP-1 medicines is disrupting that narrative. These drugs act on biological pathways involved in appetite, satiety and energy regulation, making it harder to pretend that obesity is simply a matter of willpower.
New evidence presented at the International Congress on Obesity strengthens the case for medical treatment.
Researchers combined nine randomised trials involving 756 young people with obesity but without diabetes. Those receiving GLP-1 medicines lost an average of just over 5 kg more than those receiving placebo or standard care. They also showed improvements in age-adjusted BMI, systolic blood pressure and reported quality of life.
The result is important.
It is not a licence to declare the question settled.
Four of the nine trials involved between 12 and 44 participants and lasted no longer than 24 weeks. The five larger studies followed participants for between 52 and 68 weeks. Although the overall age range extended from six to 18, the average participant was approximately 14 or 15, and the strongest evidence remains among adolescents aged 12 and older.
That matters because a treatment started during adolescence may continue for years.
A 68-week trial can show whether weight falls and common adverse effects emerge. It cannot fully answer what happens through puberty, the transition into adult care or repeated cycles of treatment and discontinuation.
Effective does not mean risk-free
The pooled analysis found a manageable short-term safety profile, but nausea was around three times more common among participants receiving GLP-1 treatment.
The current US prescribing information for Wegovy provides a more concrete picture. In its adolescent trial, nausea occurred in 42% of participants receiving semaglutide, vomiting in 36% and diarrhoea in 22%. Gallstones were reported in 3.8% of treated participants and none receiving placebo.
These effects may be manageable with dose adjustment, monitoring and appropriate support.
They are not trivial for a young person attending school, participating in sport or navigating a relationship with food that may already be complicated by stigma and dieting.
This is why paediatric GLP-1 treatment cannot be reduced to an injection and a follow-up weigh-in.
Clinicians need to assess nutrition, growth, gastrointestinal symptoms, mental health and possible disordered eating. Families need practical guidance on what the treatment can achieve and what remains unknown.
The prescription is reaching the market faster than the pathway
US paediatric guidance already recommends offering approved obesity pharmacotherapy to eligible adolescents aged 12 and older alongside intensive behavioural and lifestyle care. Semaglutide and liraglutide are among the GLP-1 medicines authorised for adolescent weight management.
But eligibility does not equal access.
A 2026 US study examined more than two million adolescents with obesity and found that only 0.9% received a GLP-1 prescription between 2021 and July 2025. Adolescents insured through Medicaid had substantially lower odds of receiving one than those with commercial coverage. Prescribing was also lower among Black and Hispanic adolescents, young people in disadvantaged neighbourhoods and those living outside urban areas.
The children carrying the greatest burden of obesity may therefore have the least access to its most effective treatments.
Coverage restrictions are only one barrier. Many regions lack multidisciplinary paediatric obesity clinics. Primary-care clinicians may have limited time, training or administrative support for prior authorisation and continuing monitoring. Families may have to travel long distances for specialist appointments.
A medicine designed for chronic care cannot succeed inside a temporary pathway.
Treatment cannot replace prevention
There is another political risk.
Governments may interpret effective medicines as permission to avoid changing the environments contributing to childhood obesity.
GLP-1 drugs cannot regulate food marketing to children.
They cannot make nutritious meals affordable.
They cannot create safe places to exercise or give families time to cook.
They cannot remove poverty, stigma or the dominance of ultra-processed products in many children’s diets.
Medical treatment and population prevention are not competing ideas. Children already living with obesity deserve effective care, while governments remain responsible for reducing the conditions that make unhealthy choices easier and healthier choices harder.
The new findings move the debate forward because they show that GLP-1 medicines can improve more than the number on a scale.
But the phrase “safe and effective for children” needs a footnote.
Safe over how many years?
Effective for which ages?
Accessible to which families?
Supported by what kind of care?
Adolescents are entering the GLP-1 era.
The science is moving faster than the systems expected to look after them.
